Cargando…

The dynamics of HER2 status in esophageal adenocarcinoma

Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Creemers, Aafke, Ebbing, Eva A., Hooijer, Gerrit K.J., Stap, Lisanne, Jibodh-Mulder, Rajni A., Gisbertz, Susanne S., van Berge Henegouwen, Mark I., van Montfoort, Maurits L., Hulshof, Maarten C.C.M., Krishnadath, Kausilia K., van Oijen, Martijn G.H., Bijlsma, Maarten F., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/
https://www.ncbi.nlm.nih.gov/pubmed/29928485
http://dx.doi.org/10.18632/oncotarget.25507
_version_ 1783332378477854720
author Creemers, Aafke
Ebbing, Eva A.
Hooijer, Gerrit K.J.
Stap, Lisanne
Jibodh-Mulder, Rajni A.
Gisbertz, Susanne S.
van Berge Henegouwen, Mark I.
van Montfoort, Maurits L.
Hulshof, Maarten C.C.M.
Krishnadath, Kausilia K.
van Oijen, Martijn G.H.
Bijlsma, Maarten F.
Meijer, Sybren L.
van Laarhoven, Hanneke W.M.
author_facet Creemers, Aafke
Ebbing, Eva A.
Hooijer, Gerrit K.J.
Stap, Lisanne
Jibodh-Mulder, Rajni A.
Gisbertz, Susanne S.
van Berge Henegouwen, Mark I.
van Montfoort, Maurits L.
Hulshof, Maarten C.C.M.
Krishnadath, Kausilia K.
van Oijen, Martijn G.H.
Bijlsma, Maarten F.
Meijer, Sybren L.
van Laarhoven, Hanneke W.M.
author_sort Creemers, Aafke
collection PubMed
description Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the primary tumor. However, this status may change over the course of treatment or disease progression. The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome. Discordance, defined as any change in HER2 status between matched biopsy and post-neoadjuvant chemoradiation therapy resection specimen (N = 170), or between matched resection specimen and recurrence of patients not eligible for curative treatment (N = 61), was determined using the standardized HER2 status scoring system. Clinically relevant positive discordance was defined as a change to HER2 positive status, as this would imply eligibility for HER2-targeted therapy. A difference in HER2 status between biopsy and resection specimen and resection specimen and metachronous recurrence was observed in 2.1% (n = 3) and 3.3% (n = 2) of the paired cases, respectively. Clinically relevant discordance was detected in 1.4% (n = 2) of the resectable patients and 1.6% (n = 1) of the patients with recurrent disease. Patients with HER2-positive status tumors before start of neoadjuvant treatment showed better overall survival, but not statistically significant. No association between HER2 status discordance and survival was found. Clinically relevant HER2 status discordance was observed and in order to prevent under-treatment of patients, the assessment of HER2 status in the metastatic setting should preferably be performed on the most recently developed lesions if the previous HER2 assessment on archival material of the primary tumor was negative.
format Online
Article
Text
id pubmed-6003553
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-60035532018-06-20 The dynamics of HER2 status in esophageal adenocarcinoma Creemers, Aafke Ebbing, Eva A. Hooijer, Gerrit K.J. Stap, Lisanne Jibodh-Mulder, Rajni A. Gisbertz, Susanne S. van Berge Henegouwen, Mark I. van Montfoort, Maurits L. Hulshof, Maarten C.C.M. Krishnadath, Kausilia K. van Oijen, Martijn G.H. Bijlsma, Maarten F. Meijer, Sybren L. van Laarhoven, Hanneke W.M. Oncotarget Research Paper Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the primary tumor. However, this status may change over the course of treatment or disease progression. The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome. Discordance, defined as any change in HER2 status between matched biopsy and post-neoadjuvant chemoradiation therapy resection specimen (N = 170), or between matched resection specimen and recurrence of patients not eligible for curative treatment (N = 61), was determined using the standardized HER2 status scoring system. Clinically relevant positive discordance was defined as a change to HER2 positive status, as this would imply eligibility for HER2-targeted therapy. A difference in HER2 status between biopsy and resection specimen and resection specimen and metachronous recurrence was observed in 2.1% (n = 3) and 3.3% (n = 2) of the paired cases, respectively. Clinically relevant discordance was detected in 1.4% (n = 2) of the resectable patients and 1.6% (n = 1) of the patients with recurrent disease. Patients with HER2-positive status tumors before start of neoadjuvant treatment showed better overall survival, but not statistically significant. No association between HER2 status discordance and survival was found. Clinically relevant HER2 status discordance was observed and in order to prevent under-treatment of patients, the assessment of HER2 status in the metastatic setting should preferably be performed on the most recently developed lesions if the previous HER2 assessment on archival material of the primary tumor was negative. Impact Journals LLC 2018-06-01 /pmc/articles/PMC6003553/ /pubmed/29928485 http://dx.doi.org/10.18632/oncotarget.25507 Text en Copyright: © 2018 Creemers et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Creemers, Aafke
Ebbing, Eva A.
Hooijer, Gerrit K.J.
Stap, Lisanne
Jibodh-Mulder, Rajni A.
Gisbertz, Susanne S.
van Berge Henegouwen, Mark I.
van Montfoort, Maurits L.
Hulshof, Maarten C.C.M.
Krishnadath, Kausilia K.
van Oijen, Martijn G.H.
Bijlsma, Maarten F.
Meijer, Sybren L.
van Laarhoven, Hanneke W.M.
The dynamics of HER2 status in esophageal adenocarcinoma
title The dynamics of HER2 status in esophageal adenocarcinoma
title_full The dynamics of HER2 status in esophageal adenocarcinoma
title_fullStr The dynamics of HER2 status in esophageal adenocarcinoma
title_full_unstemmed The dynamics of HER2 status in esophageal adenocarcinoma
title_short The dynamics of HER2 status in esophageal adenocarcinoma
title_sort dynamics of her2 status in esophageal adenocarcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/
https://www.ncbi.nlm.nih.gov/pubmed/29928485
http://dx.doi.org/10.18632/oncotarget.25507
work_keys_str_mv AT creemersaafke thedynamicsofher2statusinesophagealadenocarcinoma
AT ebbingevaa thedynamicsofher2statusinesophagealadenocarcinoma
AT hooijergerritkj thedynamicsofher2statusinesophagealadenocarcinoma
AT staplisanne thedynamicsofher2statusinesophagealadenocarcinoma
AT jibodhmulderrajnia thedynamicsofher2statusinesophagealadenocarcinoma
AT gisbertzsusannes thedynamicsofher2statusinesophagealadenocarcinoma
AT vanbergehenegouwenmarki thedynamicsofher2statusinesophagealadenocarcinoma
AT vanmontfoortmauritsl thedynamicsofher2statusinesophagealadenocarcinoma
AT hulshofmaartenccm thedynamicsofher2statusinesophagealadenocarcinoma
AT krishnadathkausiliak thedynamicsofher2statusinesophagealadenocarcinoma
AT vanoijenmartijngh thedynamicsofher2statusinesophagealadenocarcinoma
AT bijlsmamaartenf thedynamicsofher2statusinesophagealadenocarcinoma
AT meijersybrenl thedynamicsofher2statusinesophagealadenocarcinoma
AT vanlaarhovenhannekewm thedynamicsofher2statusinesophagealadenocarcinoma
AT creemersaafke dynamicsofher2statusinesophagealadenocarcinoma
AT ebbingevaa dynamicsofher2statusinesophagealadenocarcinoma
AT hooijergerritkj dynamicsofher2statusinesophagealadenocarcinoma
AT staplisanne dynamicsofher2statusinesophagealadenocarcinoma
AT jibodhmulderrajnia dynamicsofher2statusinesophagealadenocarcinoma
AT gisbertzsusannes dynamicsofher2statusinesophagealadenocarcinoma
AT vanbergehenegouwenmarki dynamicsofher2statusinesophagealadenocarcinoma
AT vanmontfoortmauritsl dynamicsofher2statusinesophagealadenocarcinoma
AT hulshofmaartenccm dynamicsofher2statusinesophagealadenocarcinoma
AT krishnadathkausiliak dynamicsofher2statusinesophagealadenocarcinoma
AT vanoijenmartijngh dynamicsofher2statusinesophagealadenocarcinoma
AT bijlsmamaartenf dynamicsofher2statusinesophagealadenocarcinoma
AT meijersybrenl dynamicsofher2statusinesophagealadenocarcinoma
AT vanlaarhovenhannekewm dynamicsofher2statusinesophagealadenocarcinoma